Fecal calprotectin predicts relapse and histological mucosal healing in ulcerative colitis

Inflammatory Bowel Diseases

Volumn 22, Issue 5, 2016, Pages 1042-1048

  Theede, Klaus ^a   Holck, Susanne ^a   Ibsen, Per ^a   Kallemose, Thomas ^a   Nordgaard Lassen, Inge ^a   Nielsen, Anette Mertz ^a  

^a HVIDOVRE HOSPITAL   (Denmark)

Author keywords

endoscopy; fecal calprotectin; mucosal healing; relapse; ulcerative colitis

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALGRANULIN;

ADULT; ARTICLE; COLON MUCOSA; DIGESTIVE SYSTEM DISEASE ASSESSMENT; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MAYO ENDOSCOPIC SCORE; MAYO SCORE; MUCOSAL HEALING; NEUTROPHIL; OBSERVATIONAL STUDY; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECTUM BIOPSY; RELAPSE; REMISSION; SIGMOIDOSCOPY; SMOKING; ULCER HEALING; ULCERATIVE COLITIS; CHEMISTRY; COMPLICATION; FECES; INFLAMMATION; METABOLISM; MUCOSA; PATHOLOGY; PROGNOSIS; RECURRENT DISEASE; WOUND HEALING;

ADULT; BIOMARKERS; COLITIS, ULCERATIVE; FECES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MUCOUS MEMBRANE; PROGNOSIS; PROSPECTIVE STUDIES; RECURRENCE; SIGMOIDOSCOPY; WOUND HEALING;

EID: 84964870223     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000736     Document Type: Article

References (32)

1. D'Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007; 132: 763-786
2. Frøslie KF, Jahnsen J, Moum BA, et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007; 133: 412-422
3. Ardizzone S, Cassinotti A, Duca P, et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol. 2011; 9: 483-489.e3
4. Neurath MF, Travis SPL. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut. 2012; 61: 1619-1635
5. Papi C, Fascì-Spurio F, Rogai F, et al. Mucosal healing in inflammatory bowel disease: treatment efficacy and predictive factors. Dig Liver Dis. 2013; 45: 978-985
6. Theede K, Kiszka-Kanowitz M, Nordgaard-Lassen I, et al. The impact of endoscopic inflammation and mucosal heling on health related quality of life in ulcerative colitis patients. J Crohns Colitis. 2015; 8: 625-632
7. Røseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol. 1999; 34: 50-54
8. D'Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012; 18: 2218-2224
9. Schoepfer AM, Beglinger C, Straumann A, et al. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis. 2009; 15: 1851-1858
10. Theede K, Holck S, Ibsen P, et al. Level of fecal calprotectin correlates with endoscopic and histologic inflammation and identifies patients with mucosal healing of ulcerative colitis. Clin Gastroenterol Hepatol. 2015; 13: 1929-1936
11. García-Sánchez V, Iglesias-Flores E, González R, et al. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis' J Crohns Colitis. 2010; 4: 144-152
12. Vos De M, Louis EJ, Jahnsen J, et al. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy. Inflamm Bowel Dis. 2013; 19: 2111-2117
13. Gisbert JP, Bermejo F, Pérez-Calle JL, et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis. 2009; 15: 1190-1198
14. Costa F, Mumolo MG, Ceccarelli L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut. 2005; 54: 364-368
15. Molander P, Af Björkesten CG, Mustonen H, et al. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFa blocking agents. Inflamm Bowel Dis. 2012; 18: 2011-2017
16. Vos De M, Dewit O, D'Haens G, et al. Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis. J Crohns Colitis. 2012; 6: 557-562
17. Ho GT, Mowat C, Goddard CJ, et al. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther. 2004; 19: 1079-1087
18. Theede K, Kiszka-Kanowitz M, Mertz Nielsen A, et al. The correlation between fecal calprotectin, simple clinical colitis activity index and biochemical markers in ulcerative colitis during high-dose steroid treatment. Scand J Gastroenterol. 2014; 49: 418-423
19. Mosli MH, Zou G, Garg SK, et al. C-Reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and Meta-Analysis. Am J Gastroenterol. 2015; 110: 802-819
20. Bessissow T, Lemmens B, Ferrante M, et al. Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healing. Am J Gastroenterol. 2012; 107: 1684-1692
21. Riley Sa, Mani V, Goodman MJ, et al. Microscopic activity in ulcerative colitis: what does it mean'. Gut. 1991; 32: 174-178
22. Guardiola J, Lobatón T, Rodríguez-Alonso L, et al. Fecal level of calprotectin identifies histologic inflammation in patients with ulcerative colitis in clinical and endoscopic remission. Clin Gastroenterol Hepatol. 2014; 12: 1865-1870
23. Mosli MH, Feagan BG, Sandborn WJ, et al. Histologic evaluation of ulcerative colitis: a systematic review of disease activity indices. Inflamm Bowel Dis. 2014; 20: 564-575
24. Gupta RB, Harpaz N, Itzkowitz S, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology. 2007; 133: 1099-1105; quiz 1340-1
25. Fiel M, Qin L, Suriawinata A, et al. Histological grading of disease activity in chronic IBD: inter- And intra-observer variation among pathologists with different levels of experience. Mod Pathol. 2003; 16: 118A.
26. Tibble JA, Sigthorsson G, Bridger S, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000; 119: 15-22
27. Yamamoto T, Shiraki M, Bamba T, et al. Fecal calprotectin and lactoferrin as predictors of relapse in patients with quiescent ulcerative colitis during maintenance therapy. Int J Colorectal Dis. 2014; 29: 485-491
28. Baars JE, Nuij VJ, Oldenburg B, et al. Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation. Inflamm Bowel Dis. 2012; 18: 1634-1640
29. Bastida G, Beltrán B. Ulcerative colitis in smokers, non-smokers and exsmokers. World J Gastroenterol. 2011; 17: 2740-2747
30. Beaugerie L, Massot N, Carbonnel F, et al. Impact of cessation of smoking on the course of ulcerative colitis. Am J Gastroenterol. 2001; 96: 2113-2116
31. Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology. 2011; 140: 1817-1826.e2
32. Sherwood RA. Faecal markers of gastrointestinal inflammation. J Clin Pathol. 2012; 65: 981-985